Evidence map›Paper›PMID 26612523›Full record

ReviewBMJ (Clinical research ed.)2015

Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Chandra Mohan, Shervin Assassi

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMJ (Clinical research ed.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 5 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Cardio-Rheumatic Diseases: Inflammasomes Behaving Badly.International journal of molecular sciences · 2025
    Review
  8. Review
  9. The Lung in Rheumatoid Arthritis-Friend or Enemy?International journal of molecular sciences · 2024
    Review
  10. Review
  11. Review
  12. Review
  13. Characterization of serum biomarkers and antibody responses againstFrontiers in cellular and infection microbiology · 2022
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Chandra MohanDepartment of Biomedical Engineering, University of Houston, Houston, TX 77204, USA.
Shervin AssassiDivision of Rheumatology, University of Texas Health Science Center at Houston, Houston shervin.assassi@uth.tmc.edu.
The University of Texas Health Science Center at Houston · USUniversity of Houston · US

Funding

Molecular Markers for Progression of Pulmonary Fibrosis in Systemic SclerosisK23AR061436 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ASSASSI, SHERVIN · 2011 to 2014
$494k
NIAMS NIH HHS K23 AR061436NIAMS NIH HHS K23-AR-061436
6 · The paper itself

Abstract

Serological and proteomic biomarkers can help clinicians diagnose rheumatic diseases earlier and assess disease activity more accurately. These markers have been incorporated into the recently revised classification criteria of several diseases to enable early diagnosis and timely initiation of treatment. Furthermore, they also facilitate more accurate subclassification and more focused monitoring for the detection of certain disease manifestations, such as lung and renal involvement. These biomarkers can also make the assessment of disease activity and treatment response more reliable. Simultaneously, several new serological and proteomic biomarkers have become available in the routine clinical setting--for example, a protein biomarker panel for rheumatoid arthritis and a myositis antibody panel for dermatomyositis and polymyositis. This review will focus on commercially available antibody and proteomic biomarkers in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (scleroderma), dermatomyositis and polymyositis, and axial spondyloarthritis (including ankylosing spondylitis). It will discuss how these markers can facilitate early diagnosis as well as more accurate subclassification and assessment of disease activity in the clinical setting. The ultimate goal of current and future biomarkers in rheumatic diseases is to enable early detection of these diseases and their clinical manifestations, and to provide effective monitoring and treatment regimens that are tailored to each patient's needs and prognosis.

Indexed as

Acute-Phase ProteinsAutoantibodiesBiomarkersEarly DiagnosisHumansPrognosisProteomicsRheumatic DiseasesRh-Hr Blood-Group SystemAcute-Phase ProteinsAutoantibodiesBiomarkersRh-Hr Blood-Group System

Identifiers

PMID26612523
PMCPMC6882504
OpenAlexW2173754051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.